BR112015012458A2 - anticorpos monoclonais humanizados contra a proteína c ativada e usos destes - Google Patents

anticorpos monoclonais humanizados contra a proteína c ativada e usos destes

Info

Publication number
BR112015012458A2
BR112015012458A2 BR112015012458A BR112015012458A BR112015012458A2 BR 112015012458 A2 BR112015012458 A2 BR 112015012458A2 BR 112015012458 A BR112015012458 A BR 112015012458A BR 112015012458 A BR112015012458 A BR 112015012458A BR 112015012458 A2 BR112015012458 A2 BR 112015012458A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
activated protein
humanized monoclonal
humanized
protein
Prior art date
Application number
BR112015012458A
Other languages
English (en)
Portuguese (pt)
Inventor
Tebbe Jan
Kim Ji-Yun
Zhao Xiao-Yan
Zhu Ying
Wang Zhuozhi
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BR112015012458A2 publication Critical patent/BR112015012458A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015012458A 2012-11-29 2013-11-27 anticorpos monoclonais humanizados contra a proteína c ativada e usos destes BR112015012458A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731368P 2012-11-29 2012-11-29
PCT/US2013/072137 WO2014085527A1 (en) 2012-11-29 2013-11-27 Humanized monoclonal antibodies against activated protein c and uses thereof

Publications (1)

Publication Number Publication Date
BR112015012458A2 true BR112015012458A2 (pt) 2018-02-06

Family

ID=50828440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012458A BR112015012458A2 (pt) 2012-11-29 2013-11-27 anticorpos monoclonais humanizados contra a proteína c ativada e usos destes

Country Status (17)

Country Link
US (2) USRE49099E1 (cg-RX-API-DMAC7.html)
EP (1) EP2925360A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016501875A (cg-RX-API-DMAC7.html)
KR (1) KR20150088853A (cg-RX-API-DMAC7.html)
CN (1) CN104936618A (cg-RX-API-DMAC7.html)
AR (1) AR093672A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013352260A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012458A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892748A1 (cg-RX-API-DMAC7.html)
HK (1) HK1215174A1 (cg-RX-API-DMAC7.html)
IL (1) IL238920A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015006738A (cg-RX-API-DMAC7.html)
RU (1) RU2015125343A (cg-RX-API-DMAC7.html)
SG (1) SG11201504035PA (cg-RX-API-DMAC7.html)
TW (1) TW201437229A (cg-RX-API-DMAC7.html)
UY (1) UY35160A (cg-RX-API-DMAC7.html)
WO (1) WO2014085527A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2020051277A1 (en) 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
KR20240152428A (ko) * 2022-03-04 2024-10-21 주식회사 코애귤런트테라퓨틱스 활성화된 단백질 c에 대한 인간 항체 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5279956A (en) 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DE60141844D1 (de) 2000-10-02 2010-05-27 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US20030203355A1 (en) 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
SI3219328T1 (sl) * 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
BRPI0818865A2 (pt) 2007-10-26 2015-05-05 Oklahoma Med Res Found Anticorpos monoclonais contra proteína c ativada.
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof

Also Published As

Publication number Publication date
EP2925360A1 (en) 2015-10-07
US20150322164A1 (en) 2015-11-12
KR20150088853A (ko) 2015-08-03
RU2015125343A (ru) 2017-01-11
WO2014085527A1 (en) 2014-06-05
US9657111B2 (en) 2017-05-23
CA2892748A1 (en) 2014-06-05
EP2925360A4 (en) 2016-07-13
AR093672A1 (es) 2015-06-17
MX2015006738A (es) 2015-08-05
JP2016501875A (ja) 2016-01-21
HK1215174A1 (zh) 2016-08-19
TW201437229A (zh) 2014-10-01
SG11201504035PA (en) 2015-06-29
IL238920A0 (en) 2015-07-30
AU2013352260A1 (en) 2015-06-11
UY35160A (es) 2014-06-30
CN104936618A (zh) 2015-09-23
USRE49099E1 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
IL290613A (en) Humanized or chimeric cd3 antibodies
IL283173A (en) Human igg1 fc region variants and uses thereof
IL263466A (en) Anti-cd3 antibodies and methods of use
PT4459282T (pt) Anticorpo monoclonal contra interleucina-31
IL263320A (en) Anti-hemagglutinin antibodies and methods of use
PL3613439T3 (pl) Chimeryczny receptor antygenowy i sposoby jego zastosowania
IL237737A0 (en) Human monoclonal antibodies against pd-l1 and methods of use
PL3789038T3 (pl) Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47
BR112014018005A2 (pt) uso de complexo não covalente imobilizado e variante de região fc de isotipo igg1 humano
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
IL229469B (en) Human immunodeficiency virus neutralizing antibodies and methods of use therof
SMT201400187B (it) Il-6 e recettore di il-6 umanizzati
CO6980627A2 (es) Anticuerpos anti-pfh-tau y sus usos
DK3978522T3 (da) Humane antistoffer over for Fel D1 og fremgangsmåder til anvendelse deraf
PT2580243T (pt) Anticorpos contra cd38 humana
CA3276932A1 (en) Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
CL2016001519A1 (es) Anticuerpos anti-tau(ps422) humanizados y métodos de utilización
LT2776469T (lt) Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
HRP20180728T1 (hr) Humanizirana protutijela koja prepoznaju alfa-sinuklein
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
SG11201404751UA (en) Modified fc region of antibody
EP3418306C0 (en) IMPROVED SET OF BISPECIFIC ANTIBODIES
IL232055A0 (en) Anti-htra1 antibodies and methods of use
LT3539986T (lt) Vėžio gydymas panaudojant humanizuotą anti-cd19 chimerinį antigeno receptorių

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]